Literature DB >> 15667331

Acquired glucose sensitivity of k-ras transformed fibroblasts.

F Chiaradonna1, C Magnani, E Sacco, R Manzoni, L Alberghina, M Vanoni.   

Abstract

Mutational activation of the ras gene is critical for the onset of different malignant phenotypes. We constructed a dominant negative mutant (GEF-DN) of a Ras activator protein (guanine nucleotide-exchange factor) that upon over-expression in k-ras transformed NIH 3T3 fibroblasts strongly reduces intracellular Ras*GTP, reverting these cells to wild-type phenotype for morphology, anchorage-independent growth and reduction of tumour formation in nude mice. Here we review evidence showing that the enhanced proliferation potential of NIH-ras cells requires high initial glucose concentration in the medium and sustained Ras pathway activation. The exquisite sensitivity of NIH-ras fibroblasts to a shortage in nutrient and energy supply highlights an acquired fragility of cancer cells that may be exploited for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15667331     DOI: 10.1042/BST0330297

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  3 in total

1.  Targeting of several glycolytic enzymes using RNA interference reveals aldolase affects cancer cell proliferation through a non-glycolytic mechanism.

Authors:  Carolyn Ritterson Lew; Dean R Tolan
Journal:  J Biol Chem       Date:  2012-10-23       Impact factor: 5.157

Review 2.  KRAS: feeding pancreatic cancer proliferation.

Authors:  Kirsten L Bryant; Joseph D Mancias; Alec C Kimmelman; Channing J Der
Journal:  Trends Biochem Sci       Date:  2014-01-02       Impact factor: 13.807

3.  Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.

Authors:  Daniela Gaglio; Christian M Metallo; Paulo A Gameiro; Karsten Hiller; Lara Sala Danna; Chiara Balestrieri; Lilia Alberghina; Gregory Stephanopoulos; Ferdinando Chiaradonna
Journal:  Mol Syst Biol       Date:  2011-08-16       Impact factor: 11.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.